Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
Growth Seen In First Full Quarter With Dual Migraine Indications
Oct 05 2021
•
By
Mandy Jackson
Nurtec ODT revenue grew from $43.8m in Q1 to $93m in Q2 and now $136m in Q3 • Source: Alamy
More from New Products
More from Scrip